NKTR

Nektar Therapeutics is a clinical-stage immunotherapy company developing immunomodulatory agents targeting autoimmune diseases and oncology. Its lead program rezpegaldesleukin is a potential first-in-class IL-2 receptor agonist designed to expand regulatory T cells and is currently in Phase 2b development for moderate-to-severe atopic dermatitis and severe-to-very severe alopecia areata, with additional Phase 2 evaluation in new-onset type 1 diabetes. The company also has the oncology candidate NKTR-255 in clinical development and preclinical-stage autoimmune programs including NKTR-0165 and NKTR-0166.

Pipeline

Catalyst Calendar